Thu, Jul 31, 2014, 10:53 AM EDT - U.S. Markets close in 5 hrs 7 mins

Recent

% | $
Click the to save as a favorite.

Curis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • desert_dweller93 desert_dweller93 Jan 26, 2013 1:36 PM Flag

    per eriv the triple won't work

    Hopefully for all Curis investors, his prediction turns out wrong. While he says it won't work, this scientist says it might. See the discussion board at Google for the link :

    Obviously things could have changed since this was reported back in June, and it was based on a small population, but read what the scientist had to say:

    Inhibiting Hedgehog Signaling Pathway May Improve Pancreatic Cancer Treatment

    June 19, 2012

    New approach has potential to change the way pancreatic cancer is treated.
    GDC-0449 targets the Hedgehog signaling pathway.
    Inhibiting this pathway may improve the efficacy of chemotherapy.
    LAKE TAHOE, Nev. — Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challengesconference, held here June 18-21.

    “We believe that GDC-0449 has the potential to change the approach to treating pancreatic cancer,” said Edward J. Kim, M.D., Ph.D., a medical oncologist at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Mich.

    GDC-0449 targets the Hedgehog signaling pathway. This pathway is normally silent in the adult pancreas but it is switched on in patients with pancreatic cancer and contributes to the desmoplastic stroma that is characteristic of this disease.

    “This dense stroma is believed to contribute to resistance to chemotherapy by presenting a physical barrier to chemotherapy delivery,” Kim explained.

    In addition, Hedgehog levels are increased in pancreatic cancer stem cells. Cancer stem cells are a subset of cancer cells present in a tumor that are believed not only to drive tumor growth by generating bulk tumor cells, but to also be particularly resistant to standard therapies like chemotherapy and radiation.

    “Even if a therapy succeeds in obtaining a response, cancer stem cells may persist and contribute to resistance and progression of disease,” Kim said. “Having found that pancreatic cancer stem cells have higher Hedgehog levels than bulk cancer cells, we were interested in determining whether targeting the Hedgehog signaling pathway and, therefore, the cancer stem cells might lead to improved outcomes in pancreatic cancer.”

    GDC-0449 targets the Smoothened (SMO) protein in the Hedgehog signaling pathway. It has been approved for use in advanced basal cell carcinoma. Kim and his colleagues felt that treating patients with pancreatic cancer first with GDC-0449 and then with the standard chemotherapeutic drug gemcitabine might disrupt the desmoplastic stroma and improve the efficacy of the chemotherapy.

    They evaluated this strategy in treatment-naive patients with advanced pancreatic cancer. Patients underwent needle biopsies of the cancer before and after taking GDC-0449 for three weeks to study the effects of GDC-0449 on the Hedgehog pathway signals, tumor stroma and pancreatic cancer stem cells. Gemcitabine was added to GDC-0449 following the second biopsy.

    Five patients achieved partial response, and another four patients had stable disease, yielding a 50 percent progression-free survival rate at three months.

    “New ways to treat pancreatic cancer are needed to improve response to therapy and ultimately patient outcomes,” Kim said, adding that he hopes data from the biopsy specimens will help identify predictive markers to determine who would benefit from this combination treatment.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Stock wouldn't drop so much anyways with EMA approval and European market pending, not to mention an uptick in sales this year in general. It would have a minimal effect in comparison to those two catalysts.

      Sentiment: Buy

    • yes, this is the gem/vis trial (not the triple that eriv was referring to) and dr kim is at the cancer center in michigan. this one looks promising according to dr kim. primary was due in dec. the question is, is gem/vis better than gem/nab-pac?
      thanks

      • 1 Reply to docihi
      • docihi, what about this snippet from the su2c site? Isn't this the 3 drug combo he is talking about? Doesn't this sound promising? Things may have changed since they reported this and maybe they weren't even talking about the hh combo although I believe they were? Thoughts?

        Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer

        30 month milestones
        The Team has fully enrolled the 842 patients for its double blind phase III clinical trial and data analysis has begun. The phase II clinical trial of a three-drug combination therapy for patients with advanced pancreatic cancer has continued and, after 6 months follow up, the Team observes a partial response in 33% of the patients and stable disease in another 48% of the patients.

        Sentiment: Strong Buy

 
CRIS
2.00+0.12(+6.39%)10:53 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.